Sex Hormone-Binding Globulin as a marker for the thrombotic risk of hormonal contraceptives: reply to a rebuttal

Author(s):
Raps, M.; Helmerhorst, F.M.; Fleischer, K.; Hylckama, V.A. van; Stegeman, B.H.; Thomassen, S.; Rosendaal, F.R.; Rosing, J.; Ballieux, B.E.P.B.; Vliet, H.A.A.M. van
Published
2012
Publication type
Other

Abstract

Kluft et al. question the design of our recent study regarding Sex Hormone-Binding Globulin (SHBG) as marker for the risk of venous thrombosis during use of hormonal contraceptives (1). They state that when measured only in women 'on-treatment', SHBG showed a very weak association with normalized activated protein C sensitivity ratios (nAPCsr) determined with the thrombin generation-based APC resistance test. Hence, in their opinion SHBG is not a surrogate marker for venous thrombosis. They claim this statement is supported by a recent publication of Stegeman et al. (2). © 2012 International Society on Thrombosis and Haemostasis.

Date issued
2012-11-24
Language
English
hdl
1887/119024
doi
10.1111/jth.12080